Rod MacKenzie, Ph.D., is Group Senior Vice President and Head of Pfizer PharmaTherapeutics Research and Development. Rod is responsible for an international, cross-disciplinary network of scientists advancing experimental therapies in multiple areas including cardiovascular and metabolic diseases; neuroscience; and pain and sensory disorders. PharmaTherapeutics also houses comparative medicine and Pfizer’s leading medicinal chemistry and small molecule discovery and development capabilities.
“Pfizer has a strong heritage as a leader in areas of major public health challenge, such as cardiovascular, metabolic and neurological diseases and pain. We continue to break new scientific ground each day, combining our expertise with insight from our collaborators.”
Group Senior Vice President and Head, PharmaTherapeutics Research and Development
Rod MacKenzie, Ph.D., is Group Senior Vice President and Head of PharmaTherapeutics Research and Development at Pfizer. In this role, he is responsible for overseeing the Cardiovascular & Metabolic Diseases, Pain & Sensory Disorders and Neuroscience Research Units. In addition, he is responsible for all medicinal chemistry at Pfizer, as well as Small Molecule Pharmaceutical Sciences, Pharmacokinetics, Dynamics & Metabolism and Comparative Medicine.
Dr. MacKenzie also serves as site director for the Groton, Conn. research laboratories, which is Pfizer’s largest global R&D facility.
Dr. MacKenzie joined Pfizer in 1986, as a research scientist in Sandwich, U.K., where he co-invented Enablex® (darifenacin) and conducted medicinal chemistry research in cardiovascular, gastrointestinal, sexual heath, urology, and allergy and respiratory diseases. Since then, Dr. MacKenzie has held numerous leadership positions at Pfizer, including Senior Vice President and Head of Worldwide Research, Head of Discovery Chemistry in Sandwich, U.K., Head of the Discovery Technology Center in Cambridge, Mass., Head of Discovery Research in Ann Arbor, Mich., and Head of Drug Safety R&D. He was appointed Senior Vice President, Head of Worldwide Research for Pfizer in February 2007, and to his current role in 2010.
Dr. MacKenzie represents Pfizer on the Board of Directors for ViiV Healthcare, a global specialist HIV company established by Pfizer and GlaxoSmithKline to deliver advances in treatment and care for people living with HIV.
Dr. MacKenzie graduated from the University of Glasgow with a 1st Class Honors degree in chemistry, and completed his Ph.D. at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University in New York City studying molecular recognition with Professor W.C. Still.